June 17, 2024

Generative AI in Personalized Medicine Market Forecast 2032

The global generative AI in personalized medicine  market report provides a detailed analysis of the market dynamic. The report sheds light on the current situation of the market size, share, demand and forecast 2023 to 2032.

Generative AI in Personalized Medicine Market Size 2023 To 2032

Key Takeaways:

  • North America is expected to dominate in the generative AI in personalized medicine market during the forecast period.
  • By personalized medicine therapeutics, the pharmaceutical segment is expected to hold a leading position in the generative AI in personalized medicine market.
  • By deployment model, the cloud-based segment is expected to carry a significant share of the generative AI in personalized medicine market during the forecast period.
  • By end-user, the hospitals and clinics segment shares the maximum CAGR during the projection period.

Report Summary

The global gas meter market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the gas meter market across the globe.

A comprehensive estimate on the gas meter market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of gas meter during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3095

Generative AI in Personalized Medicine Market Report Scope 

Report CoverageDetails
Largest MarketNorth America
Base Year2022
Forecast Period2023 to 2032
Segments CoveredBy Personalized Medicine Therapeutics, By Deployment Model, and By End-User
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized gas meter market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read:  Gas Meter Market Size To Cross USD 22.4 Bn By 2032

Generative AI in Personalized Medicine Market Players

The report includes the profiles of key gas meter market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Butterfly Network
  • Deep Genomics
  • Google LLC
  • IBM Watson Health
  • Microsoft Corporation
  • Aidoc
  • Insilico Medicine
  • PathAI
  • Tencent Holdings Ltd.
  • Neuralink Corporation
  • Johnson & Johnson

Market Segmentation

By Personalized Medicine Therapeutics

  • Pharmaceutical
  • Genomic Medicine
  • Devices

By Deployment Model

  • On-premise
  • Cloud Based

By End-User

  • Hospitals and Clinics
  • Clinical Research
  • Healthcare Organizations
  • Diagnostic Centers

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Generative AI in Personalized Medicine Market 

5.1. COVID-19 Landscape: Generative AI in Personalized Medicine Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Generative AI in Personalized Medicine Market, By Personalized Medicine Therapeutics

8.1. Generative AI in Personalized Medicine Market, by Personalized Medicine Therapeutics, 2023-2032

8.1.1 Pharmaceutical

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Genomic Medicine

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Devices

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Generative AI in Personalized Medicine Market, By Deployment Model

9.1. Generative AI in Personalized Medicine Market, by Deployment Model, 2023-2032

9.1.1. On-premise

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Cloud Based

9.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Generative AI in Personalized Medicine Market, By End-User 

10.1. Generative AI in Personalized Medicine Market, by End-User, 2023-2032

10.1.1. Hospitals and Clinics

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Clinical Research

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Healthcare Organizations

10.1.3.1. Market Revenue and Forecast (2020-2032)

10.1.4. Diagnostic Centers

10.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Generative AI in Personalized Medicine Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.1.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.1.3. Market Revenue and Forecast, by End-User (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.1.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.1.5.3. Market Revenue and Forecast, by End-User (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.2.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.2.3. Market Revenue and Forecast, by End-User (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.2.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.2.5.3. Market Revenue and Forecast, by End-User (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.2.6.3. Market Revenue and Forecast, by End-User (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.2.7.3. Market Revenue and Forecast, by End-User (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.3.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.3.3. Market Revenue and Forecast, by End-User (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.3.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.3.5.3. Market Revenue and Forecast, by End-User (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.3.6.3. Market Revenue and Forecast, by End-User (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.3.7.3. Market Revenue and Forecast, by End-User (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.4.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.4.5.3. Market Revenue and Forecast, by End-User (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.4.6.3. Market Revenue and Forecast, by End-User (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.4.7.3. Market Revenue and Forecast, by End-User (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.5.3. Market Revenue and Forecast, by End-User (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.5.4.3. Market Revenue and Forecast, by End-User (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)

11.5.5.3. Market Revenue and Forecast, by End-User (2020-2032)

Chapter 12. Company Profiles

12.1. Butterfly Network

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Deep Genomics

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Google LLC

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. IBM Watson Health

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Microsoft Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Aidoc

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Insilico Medicine

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. PathAI

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Tencent Holdings Ltd.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Neuralink Corporation

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com